The Organizing Committee is delighted to invite you to attend the Global Experts Meeting on Frontiers in Biosimilars and Biologics Congress one of its remarkable Pharmaceutical conferences, to be held during October 17-19, 2019 in Rome, Italy. Biosimilars 2019 is a global annual event. This Biosimilars and Biologics Congress 2019 will bring together scientists, researchers, business development managers, CEOs, directors, IP Attorneys, Regulatory Officials and CROs from around the world. Many biologics products are making their entry in the pharma market and experiencing a notable rise in their usage over the conventional medications.
At Biosimilars 2019 meet your target audiences from around the world focused on learning about biologics and Biosimilars. This conference would be your single best opportunity to reach the largest assemblage of participants from the Biosimilars and Biologics community.
Rome is the capital of Italy with 2,876,076 occupants in 1,285 km2. It is also the country's most populated collective. It is the fourth-most jammed city in the European Union by people inside city limits. It is a meandering, cosmopolitan city with just about 3,000 years of extensively powerful workmanship, designing and culture on display. It is the point of convergence of the Metropolitan City of Rome. It situated thirteenth most-visited city on earth in 2016, third most visited in the European Union and the most common excursion spot in Italy. Its remarkable Center is recorded by UNESCO as a World Heritage Site. It is the seat of the United Nations' Food and Agriculture Organization (FAO). The city has the base camp of various overall business associations, for example, Eni, Enel, TIM, and national and worldwide banks, for instance, Unicredit and BNL. Its business district, called EUR, is the base of various associations related to the oil business, the pharmaceutical business and budgetary organizations
The global biosimilars market size was valued at USD 4.36 billion in 2016. It is anticipated to exhibit a CAGR of 34.2% during the forecast period. Cost-effectiveness of biosimilar drugs and high prevalence of chronic disorders globally are some major factors contributing to market growth.
Biosimilar drugs are highly identical to approved biologic drugs. They possess similar medical properties in terms of potency, safety, and efficacy to original biologic products. High prevalence of chronic diseases such as diabetes, cancer, growth hormone deficiency, and anemia is expected to further fuel market expansion in near future.
As stated by the National Cancer Institute (NCI), an estimated 1,735,350 new cases of cancer are likely to be diagnosed in U.S. in 2018, and 609,640 people will die from the disease. In 2012, there were around 14 million new cancer cases and about 8.2 million cancer related deaths worldwide. Thus, there is high demand for cost-effective biosimilars for the treatment of such chronic disorders, which, in turn is expected to boost market growth
· Directors, CEO’s of Organizations
· Business Development Managers
· Chief Scientific Officers
· R&D Researchers from Biosimilar and Bioslogics Industries
· Professors, Associate Professors, Assistant Professors
· PhD Scholars
· Patent Attorneys
· Intellectual Property Attorneys
· Investment Analysts
· Association, Association presidents and professionals
· Noble laureates in Health Care and Medicine
· Bio instruments Professionals
· Bio-informatics Professionals
· Software development companies
· Research Institutes and members
· Supply Chain companies
· Manufacturing Companies
· CRO and DATA management Companies
· Training Institutes
· Business Entrepreneurs
Biosimilars Conference | Biosimilars 2019 | Biosimilars summit 2019 | Biosimilars Event | Biologics Congress | Biosimilars Congress 2019 | Biosimilars Meetings | World Biosimilars Congress | Biosimilars and Biologics
Related Societies USA
Canadian Society for Pharmaceutical Sciences (CSPS), Pharmaceutical Manufacturers Association of Canada (PMAC), American Association of Pharmacy Technicians (AAPT), American Society of Health-System Pharmacists (ASHYP). Canadian Society of Intestinal research (CSIR)
Related Societies Europe
Belgian Society of Pharmaceutical Sciences (BGFW), European Federation for Pharmaceutical Sciences (EUFEPS), Italian Society for Pharmaceutical Sciences (SISF), Association of the British Pharmaceutical Industry (ABPI). A Division of the Association for Accessibility medicines (DAAM)
For more about the tracks, please click on it.
Track 4: BPCIA and Regulatory Updates
Track 6: Biologics as therapeutics
Track 10: Biogenerics and Biopharmaceuticals
Track 12: Clinicians Approach for Biosimilars
Track 13: Globalization of Biosimilars
Track 14: Biosimilars Market and Cost Analysis
Track 15: Brexit Conundrums on Biosimilars
Track 16: Biosimilars in Crohn's disease
Track 18: BCS and IVIVC Based Biowaivers